KKKlaus-Dieter Kohnert

Klaus-Dieter Kohnert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Klaus-Dieter Kohnert has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applications of Variability Analysis Techniques for Continuous Glucose Monitoring Derived Time Series in Diabetic Patients

    by Klaus-Dieter Kohnert, Peter Heinke, Lutz Vogt, Petra Augstein, Eckhard Salzsieder

    Methods from non-linear dynamics have enhanced understanding of functional dysregulation in various diseases but received less attention in diabetes. This retrospective cross-sectional study evaluates and compares relationships between indices of non-linear dynamics and traditional glycemic variability, and their potential application in diabetes control. Continuous glucose monitoring provided data for 177 subjects with type 1 (n = 22), type 2 diabetes (n = 143), and 12 non-diabetic subjects. Each time series comprised 576 glucose values. We calculated Poincaré plot measures (SD1, SD2), shape (SFE) and area of the fitting ellipse (AFE), multiscale entropy (MSE) index, and detrended fluctuation exponents (α1, α2). The glycemic variability metrics were the coefficient of variation (%CV) and standard deviation. Time of glucose readings in the target range (TIR) defined the quality of glycemic control. The Poincaré plot indices and α exponents were higher (p < 0.05) in type 1 than in the type 2 diabetes; SD1 (mmol/l): 1.64 ± 0.39 vs. 0.94 ± 0.35, SD2 (mmol/l): 4.06 ± 0.99 vs. 2.12 ± 1.04, AFE (mmol2/l2): 21.71 ± 9.82 vs. 7.25 ± 5.92, and α1: 1.94 ± 0.12 vs. 1.75 ± 0.12, α2: 1.38 ± 0.11 vs. 1.30 ± 0.15. The MSE index decreased consistently from the non-diabetic to the type 1 diabetic group (5.31 ± 1.10 vs. 3.29 ± 0.83, p < 0.001); higher indices correlated with lower %CV values (r = -0.313, p < 0.001). In a subgroup of type 1 diabetes patients, insulin pump therapy significantly decreased SD1 (-0.85 mmol/l), SD2 (-1.90 mmol/l), and AFE (-16.59 mmol2/l2), concomitantly with %CV (-15.60). The MSE index declined from 3.09 ± 0.94 to 1.93 ± 0.40 (p = 0.001), whereas the exponents α1 and α2 did not. On multivariate regression analyses, SD1, SD2, SFE, and AFE emerged as dominant predictors of TIR (β = -0.78, -1.00, -0.29, and -0.58) but %CV as a minor one, though α1 and MSE failed. In the regression models, including SFE, AFE, and α2 (β = -0.32), %CV was not a significant predictor. Poincaré plot descriptors provide additional information to conventional variability metrics and may complement assessment of glycemia, but complexity measures produce mixed results.


  • Open Access

    Indices for Assessment of the Quality of Glycemic Control and Glucose Dynamics from Continuous Glucose Monitoring

    by Klaus-Dieter Kohnert

    Blood glucose control is a fundamental element in the management of diabetes to reduce or even prevent micro- and macro vascular complications. Many patients with diabetes can improve glycemic control by use of Continuous Glucose Monitoring (CGM) systems. However, analysis and interpretation of the datasets obtained from CGM are complicated by the many indices and measures currently proposed for assessment of glycemic variability and the quality of glycemic control


  • Associations of blood glucose dynamics with antihyperglycemic treatment and glycemic variability in type 1 and type 2 diabetes

    by K.-D. Kohnert, P. Heinke, L. Vogt, P. Augstein, A. Thomas, E. Salzsieder

    The dynamical structure of glucose fluctuation has largely been disregarded in the contemporary management of diabetes.


  • Open Access

    Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies

    by Petra Augstein, Peter Heinke, Lutz Vogt, Roberto Vogt, Christine Rackow, Klaus-Dieter Kohnert, Eckhard Salzsieder

    Continuous glucose monitoring (CGM) has revolutionised diabetes management. CGM enables complete visualisation of the glucose profile, and the uncovering of metabolic ‘weak points’. A standardised procedure to evaluate the complex data acquired by CGM, and to create patient-tailored recommendations has not yet been developed. We aimed to develop a new patient-tailored approach for the routine clinical evaluation of CGM profiles. We developed a metric allowing screening for profiles that require therapeutic action and a method to identify the individual CGM parameters with improvement potential. Fifteen parameters frequently used to assess CGM profiles were calculated for 1,562 historic CGM profiles from subjects with type 1 or type 2 diabetes. Factor analysis and varimax rotation was performed to identify factors that accounted for the quality of the profiles. We identified five primary factors that determined CGM profiles (central tendency, hyperglycaemia, hypoglycaemia, intra- and inter-daily variations). One parameter from each factor was selected for constructing the formula for the screening metric, (the ‘Q-Score’). To derive Q-Score classifications, three diabetes specialists independently categorised 766 CGM profiles into groups of ‘very good’, ‘good’, ‘satisfactory’, ‘fair’, and ‘poor’ metabolic control. The Q-Score was then calculated for all profiles, and limits were defined based on the categorised groups (<4.0, very good; 4.0–5.9, good; 6.0–8.4, satisfactory; 8.5–11.9, fair; and ≥12.0, poor). Q-Scores increased significantly (P <0.01) with increasing antihyperglycaemic therapy complexity. Accordingly, the percentage of fair and poor profiles was higher in insulin-treated compared with diet-treated subjects (58.4% vs. 9.3%). In total, 90% of profiles categorised as fair or poor had at least three parameters that could potentially be optimised. The improvement potential of those parameters can be categorised as ‘low’, ‘moderate’ and ‘high’. The Q-Score is a new metric suitable to screen for CGM profiles that require therapeutic action. Moreover, because single components of the Q-Score formula respond to individual weak points in glycaemic control, parameters with improvement potential can be identified and used as targets for optimising patient-tailored therapies.


  • Open Access

    Utility of different glycemic control metrics for optimizing management of diabetes

    by Klaus-Dieter Kohnert

    The benchmark for assessing quality of long-term glycemic control and adjustment of therapy is currently glycated hemoglobin (HbA1c). Despite its importance as an indicator for the development of diabetic complications, recent studies have revealed that this metric has some limitations; it conveys a rather complex message, which has to be taken into consideration for diabetes screening and treatment. On the basis of recent clinical trials, the relationship between HbA1c and cardiovascular outcomes in long-standing diabetes has been called into question. It becomes obvious that other surrogate and biomarkers are needed to better predict cardiovascular diabetes complications and assess efficiency of therapy. Glycated albumin, fructosamin, and 1,5-anhydroglucitol have received growing interest as alternative markers of glycemic control. In addition to measures of hyperglycemia, advanced glucose monitoring methods became available. An indispensible adjunct to HbA1c in routine diabetes care is self-monitoring of blood glucose. This monitoring method is now widely used, as it provides immediate feedback to patients on short-term changes, involving fasting, preprandial, and postprandial glucose levels. Beyond the traditional metrics, glycemic variability has been identified as a predictor of hypoglycemia, and it might also be implicated in the pathogenesis of vascular diabetes complications. Assessment of glycemic variability is thus important, but exact quantification requires frequently sampled glucose measurements. In order to optimize diabetes treatment, there is a need for both key metrics of glycemic control on a day-to-day basis and for more advanced, user-friendly monitoring methods. In addition to traditional discontinuous glucose testing, continuous glucose sensing has become a useful tool to reveal insufficient glycemic management. This new technology is particularly effective in patients with complicated diabetes and provides the opportunity to characterize glucose dynamics. Several continuous glucose monitoring (CGM) systems, which have shown usefulness in clinical practice, are presently on the market. They can broadly be divided into systems providing retrospective or real-time information on glucose patterns. The widespread clinical application of CGM is still hampered by the lack of generally accepted measures for assessment of glucose profiles and standardized reporting of glucose data. In this article, we will discuss advantages and limitations of various metrics for glycemic control as well as possibilities for evaluation of glucose data with the special focus on glycemic variability and application of CGM to improve individual diabetes management.


  • Evaluation of the Mean Absolute Glucose Change as a Measure of Glycemic Variability Using Continuous Glucose Monitoring Data

    by Klaus-Dieter Kohnert, Peter Heinke, Gert Fritzsche, Lutz Vogt, Petra Augstein, Eckhard Salzsieder

    Background: The mean absolute glucose (MAG) change, originally developed to assess associations between glycemic variability (GV) and intensive care unit mortality, has not yet been validated. We used continuous glucose monitoring (CGM) datasets from patients with diabetes to assess the validity of MAG and to quantify associations with established measures of GV. Subjects and Methods: Validation was based on retrospective analysis of 72-h CGM data collected during clinical studies involving 815 outpatients (48 with type 1 diabetes and 767 with type 2 diabetes). Measures of GV included SD around the sensor glucose, interquartile range, mean amplitude of glycemic excursions, and the continuous overlapping net glycemic action indices at 1, 3, and 6 h. MAG was calculated using 5-min, 60-min, and seven-point glucose profile sampling intervals; correlations among the variability measures and effects of sampling frequency were assessed. Results: Strong linear correlations between MAG change and classical markers of GV were documented ( r =0.587–0.809, P r =0.246 and r =0.378, respectively). The magnitude of MAG change decreased in a nonlinear fashion ( P <0.001), as intervals between glucose measurements increased. MAG change, as calculated from 5-min sensor glucose readings, did reflect relatively small differences in glucose fluctuations associated with glycemic treatment modality. Conclusions: MAG change represents a valid GV index if closely spaced sensor glucose measurements are used, but does not provide any advantage over variability indices already used for assessing diabetes control.


  • Glycaemic Variability and Pancreatic ß-cell Dysfunction

    by Klaus-Dieter Kohnert, Ernst-Joachim Freyse, Eckhard Salzsieder

    The importance of glycaemic variability (GV) as a factor in the pathophysiology of cellular dysfunction and late diabetes complications is currently a matter of debate. However, there is mounting evidence from in vivo and in vitro studies that GV has adverse effects on the cascade of physiological processes that result in chronic ß-cell dysfunctions. Glucose fluctuations more than sustained chronic hyperglycaemia can induce excessive formation of reactive oxygen (ROS) and reactive nitrogen species (RNS), ultimately leading to apoptosis related to oxidative stress. The insulinsecreting ß-cells are particularly susceptible to damage imposed by oxidative stress. Evidence from experiments, using isolated pancreatic islets or ß-cell lines, has linked intermittent high glucose, which mimicks GV under diabetic conditions, to significant impairment of ß-cell function. Several clinical studies reported a close association between GV and ßcell dysfunction, although the deleterious effects are difficult to demonstrate. Notwithstanding, early therapeutic interventions in patients with type 1 as well as type 2 diabetes, using different strategies of optimising glycaemic control, have shown that favourable outcomes on recovery and maintenance of ß-cell function correlated with reduction of GV. The purpose of the present review is to discuss the detrimental effects of GV and associations with ß-cell function as well as upcoming therapeutic strategies directed towards minimising glucose excursions, improving ß-cell recovery and preventing progressive ß-cell loss. Measuring GV has importance for management of diabetes, because it is the only one component of the dysglycaemia that reflects the degree of dysregulation of glucose homeostasis.


  • Kontinuierliches Glukosemonitoring – Was haben wir bereits gelernt?

    by Klaus-Dieter Kohnert, Lutz Vogt, Eckhard Salzsieder

    In dem Bestreben die Diabetestherapie zu optimieren und besser auf die persönlichen Bedürfnisse des Patienten einzustellen, leistet das kontinuierliche Glukosemonitoring (CGM) einen außerordentlich wichtigen Beitrag, indem es bisher nicht zugängliche Informationen über die individuelle Dynamik der Glykämie und Effektivität von Therapiemaßnahmen erschließt. Im Rahmen der Blutzuckerselbstkontrolle haben sich 2 auf der Sensortechnologie basierende Varianten in Ergänzung zu den diskreten Messungen mit dem Glukometer etabliert: Retrospektives Glukosemonitoring und Monitoring mit Echtzeit-Anzeige der Glukosewerte. Beide CGM-Varianten stellen in ihrer Durchführung unterschiedlich hohe Anforderungen an Arzt und Patient. Mithilfe computergestützter Verfahren sind die gewonnenen Messdaten und Glukoseprofile einer entsprechenden Interpretation durch den behandelnden Arzt zugänglich. Besonders schwierig einstellbare Patienten profitieren bei mehrmaliger Anwendung von CGM durch eine deutliche Verbesserung ihrer Glykämie und des Wohlbefindens. The development of the CGM technology has greatly contributed to achieve the goal of better glycemic control by providing hitherto unknown information on the efficacy of therapeutic adjustments and glucose dynamics. Two variants of CGM based on sensor technology are available: retrospective and real-time glucose monitoring. Both variants differ in their requirements for training and setup time. Computer-based evaluation procedures are available for full utilization of the CGM data by the practicing physician. Clinical study outcomes and data obtained from every-day diabetes management have shown that the use of CGM can consistently improve glycemic control. Longer duration and higher frequency of monitorings may optimize assessment of long-term glycemic control.